Technical Analysis for KRTX - Karuna Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 20.1 -3.60% -0.75
KRTX closed down 3.6 percent on Friday, August 23, 2019, on 83 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical KRTX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
20 DMA Support Bullish -3.60%
Inside Day Range Contraction -3.60%
Wide Bands Range Expansion -3.60%
20 DMA Support Bullish -3.69%
Multiple of Ten Bullish Other -3.69%
Outside Day Range Expansion -3.69%

Older signals for KRTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Biopharmaceutical Pain Schizophrenia Central Nervous System Disorders Alzheimer's Treatment Of Central Nervous System Disorders
Is KRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 29.0
52 Week Low 16.95
Average Volume 98,853
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 20.251
10-Day Moving Average 21.533
Average True Range 1.9241
ADX 18.11
+DI 16.485
-DI 16.9327
Chandelier Exit (Long, 3 ATRs ) 17.9277
Chandelier Exit (Short, 3 ATRs ) 22.7223
Upper Bollinger Band 23.5001
Lower Bollinger Band 17.0019
Percent B (%b) 0.48
BandWidth 32.088292
MACD Line 0.0738
MACD Signal Line -0.0027
MACD Histogram 0.0764
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.31
Resistance 3 (R3) 22.29 21.55 21.94
Resistance 2 (R2) 21.55 20.99 21.55 21.81
Resistance 1 (R1) 20.82 20.64 20.45 20.84 21.69
Pivot Point 20.08 20.08 19.89 20.08 20.08
Support 1 (S1) 19.35 19.52 18.98 19.37 18.51
Support 2 (S2) 18.61 19.17 18.61 18.39
Support 3 (S3) 17.88 18.61 18.26
Support 4 (S4) 17.90